Established Sell-Side M&A Leadership
- Strong activity in segments where HCIT is converging with other verticals, including life sciences, workforce management, benefits, payments, compliance, and risk management
- 2021 has started at a record pace and our pipeline points to continued robust activity in the remainder of the year
Trusted Buy-Side Advice to Clients
- Our deep insight across the HCIT industry provides invaluable strategic perspectives and buy-side intelligence to our clients
- Clients value our thoughtful, post-deal M&A road mappings
- Drawing on multiple decades of transaction structuring and execution experience, we guide buyers in optimizing price and terms
Continued Momentum in HCIT Equity and Debt Capital Markets
- We served as active bookrunner on 10 of 2021’s successful HCIT equity offerings
- Our transaction breadth in 2021 has included IPO’s, follow-on equity offerings, convertible debt and private equity placements
In addition to 2021's activity, we have advised on or underwritten many of the landmark transactions that have shaped the healthcare IT landscape over the past several years. To learn more about our transaction experience, advisory services, and perspective on the trends affecting HCIT, please contact any of our team members.